

Toll Like Receptor 3 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/TBDB7C7B1421EN.html>

Date: July 2020

Pages: 87

Price: US\$ 3,500.00 (Single User License)

ID: TBDB7C7B1421EN

Abstracts

Toll Like Receptor 3 - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Toll Like Receptor 3 - Pipeline Review, H2 2020'; Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.

The report 'Toll Like Receptor 3 - Pipeline Review, H2 2020' outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Immunology, Central Nervous System and Respiratory which include indications Melanoma, Bladder Cancer, Breast Cancer, Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Human Immunodeficiency Virus (HIV)

Infections (AIDS), Metastatic Colorectal Cancer, Ovarian Cancer, Peritoneal Cancer, Renal Cell Carcinoma, Severe Acute Respiratory Syndrome (SARS), Triple-Negative Breast Cancer (TNBC), Acute Inflammation, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Cytomegalovirus (HHV-5) Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fallopian Tube Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Herpes Labialis (Oral Herpes), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenza A Virus, H7N9 Subtype Infections, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Neuroendocrine Tumors, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Solid Tumor, Ulcerative Colitis, Unspecified Influenza Virus Infections, West Nile Virus Infections and Zika Virus Infections

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)

The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 3 (CD283 or TLR3) - Overview

Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development

13therapeutics Inc

AIM ImmunoTech Inc

Glystantis Inc

Highlight Therapeutics SL

Oncovir Inc

PrEP Biopharm Ltd

Provention Bio Inc

Tollys SAS

Yisheng Biopharma Co Ltd

Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles

Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BO-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products

Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products

Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by 13therapeutics Inc, H2 2020
Pipeline by AIM ImmunoTech Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

13therapeutics Inc
AIM ImmunoTech Inc
Glystantis Inc
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd

I would like to order

Product name: Toll Like Receptor 3 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/TBDB7C7B1421EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TBDB7C7B1421EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970